ave-1625
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT00345410)
Timeline
Indications
Mechanism of action
- Cannabinoid CB1 receptorANTAGONIST
CNR1 antagonist
Discontinued possibly due to psychiatric side effects as seen with withdrawn CNR1 antagonist rimonabant.
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)N(c1cc(F)cc(F)c1)C1CN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)C1- Mol. weight
- 497.39 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545166 ↗
Also known as
- ave1625
- ave1625
- ave-1625
- ave-1625
- ave-1625
- drinabant
- drinabant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00439634 | Phase 2 | Feb 1, 2007 | Sanofi |
| NCT00380302 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2006 | Sanofi |
| NCT00345410 | Phase 2 | Jun 1, 2006 | Dallas Diabetes and Endocrine Center, Sanofi |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 3 | 1 | 2006 |
| Dallas Diabetes and Endocrine Center | Academic/Hospital | 1 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1